Article Sidebar

PDF (Tiếng Việt)
Published: 2024-03-29
Abstract Views: 134
Views PDF (Tiếng Việt): 214
DOI: https://doi.org/10.52852/tcncyh.v175i2.2232
Issue
Vol. 175 No. 2 (2024)
Section
Các bài báo
How to Cite
Hạnh, N. T. H., Mão, C. V., & Cường, B. K. (2024). 20. Survey of TNF-α concentration and its correlation with leukocyte indicators in mice treated with anti-PD-1 monoclonal antibody and CAR-T cells combination. Journal of Medical Research, 175(2), 164-171. https://doi.org/10.52852/tcncyh.v175i2.2232

20. Survey of TNF-α concentration and its correlation with leukocyte indicators in mice treated with anti-PD-1 monoclonal antibody and CAR-T cells combination

Nguyen Thi Hien Hanh, Can Van Mao, Bui Khac Cuong

Main Article Content

Abstract

The purpose of the study is to evaluate the correlation between leukocyte indices and TNF-α levels of combination therapy of monoclonal antibody that inhibits PD-1 with CAR-T cells in the experimental animal models. We conducted an experimental, prospective, interventional study with a control group. 60 white mice were divided into 4 groups, each group of 15 animals including a control group, CAR-T cell treatment group, PD-1 inhibitor monoclonal antibody treatment group, and PD-1 combined with CAR-T cells group. After treatment, all mice were monitored for whole body condition. Their white blood cell indices and TNF-α levels were measured. TNF-α concentration in the CAR-T group was not different from the control group. TNF-α levels in the PD-1 inhibitor monoclonal antibody combined with CAR-T cells increased statistically significantly compared to the control group (p < 0.001). There is a positive correlation between TNF-α concentration and the absolute number of monocytes in the treatment group of monoclonal antibody that inhibits PD-1 combined with CAR-T cells (r = 0.578; p < 0.05 ). Through this research, we found that combining anti-PD-1 monoclonal antibodies with CAR-T cells increased TNF-α levels in mice and there was a positive correlation between TNF-α concentration and monocyte count.

Article Details

Keywords

CAR-T, PD-1, white blood cell indices, TNF-α

References

1. Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. American family physician. May 1 2014; 89(9): 731-8.
2. Srivastava S, Riddell SR. Engineering CAR-T cells: Design concepts. Trends in immunology. Aug 2015; 36(8): 494-502. doi:10.1016/j.it.2015.06.004.
3. Yip A, Webster RM. The market for chimeric antigen receptor T cell therapies. Nature reviews Drug discovery. Mar 2018; 17(3): 161-162. doi:10.1038/nrd.2017.266.
4. Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem. Jan 2022; 3(Suppl 1): 6-10. doi:10.1002/jha2.338.
5. Song W, Zhang M. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies. Clinical immunology (Orlando, Fla). May 2020; 214: 108382. doi:10.1016/j.clim.2020.108382.
6. Nguyen HH, Bui KC, Nguyen TML, et al. The safety of CAR-T cells and PD-1 antibody combination on an experimental model. Biochemical and biophysical research communications. Mar 15 2023; 649: 25-31. doi:10.1016/j.bbrc.2023.01.096.
7. Santos EW, Oliveira DCd, Hastreiter A, et al. Hematological and biochemical reference values for C57BL/6, Swiss Webster and BALB/c mice. Brazilian Journal of Veterinary Research and Animal Science. 06/17 2016; 53(2): 138-145. doi:10.11606/issn.1678-4456.v53i2p138-145.
8. Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood reviews. Mar 2019; 34: 45-55. doi:10.1016/j.blre.2018.11.002.
9. Chou CK, Turtle CJ. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. Expert opinion on biological therapy. Jun 2020; 20(6): 653-664. doi:10.1080/14712598.2020.1729735.
10. Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorganic & medicinal chemistry. Mar 1 2020; 28(5): 115327. doi:10.1016/j.bmc.2020.115327.
11. El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. SpringerPlus. 2016/09/07 2016; 5(1): 1508. doi:10.1186/s40064-016-3197-y.
12. Yakoub-Agha I, Moreau AS, Ahmad I, et al. Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC). Bulletin du cancer. Jan 2019; 106(1s): S102-s109. Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l’adulte et l’enfant: recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC). doi:10.1016/j.bulcan.2018.12.001.